NEW YORK (GenomeWeb News) – Agilent and Chungnam National University today announced a collaboration targeting glycomics.
Under the terms of the deal, the partners will develop new applications, methods, technologies, and software tools for glycan analysis. The South Korean university hopes to identify and develop biomarkers for diseases, such as cancer, resulting in the development of therapeutic antibody products.
The partnership is Agilent's first with an Asian university, the partners said.
"The knowledge gleaned from the collaboration will not only contribute toward the improvement of the biosimilars industry in Korea, but also help scientists discover new cures and develop new drugs and vaccines to treat and prevent diseases," Rod Minett, general manager of Agilent Life Sciences Group, South Asia Pacific and Korea, said in a statement.
Financial and other terms were not disclosed.
The research will be jointly led by Hyun Joo An and Rudolf Grimm. An is a professor in the department of analytical science and technology at Chungnam National University's Graduate School of Analytical Science and Technology, or GRAST, and head of the new Asia Glycomics Education Center.
Grimm is Agilent's director of science and technology and manager of collaborations in the Asia Pacific region, as well as an adjunct professor at Chungnam National University.
The agreement also calls for GRAST to develop glycomics training courses for Agilent's customers and employees. Agilent will use GRAST as a strategic glycomics reference site in Korea and Southeast Asia.